- Home
- SYT vs INTS Comparison
SYT vs INTS Comparison
Compare SYT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYT
- INTS
- Stock Information
- Founded
- SYT 2010
- INTS 2012
- Country
- SYT Japan
- INTS United States
- Employees
- SYT N/A
- INTS N/A
- Industry
- SYT Real Estate
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- SYT Finance
- INTS Health Care
- Exchange
- SYT Nasdaq
- INTS Nasdaq
- Market Cap
- SYT 41.2M
- INTS 33.4M
- IPO Year
- SYT 2023
- INTS 2023
- Fundamental
- Price
- SYT $1.74
- INTS $2.23
- Analyst Decision
- SYT
- INTS Strong Buy
- Analyst Count
- SYT 0
- INTS 3
- Target Price
- SYT N/A
- INTS $8.50
- AVG Volume (30 Days)
- SYT 7.7K
- INTS 26.6K
- Earning Date
- SYT 03-05-2025
- INTS 03-13-2025
- Dividend Yield
- SYT 0.35%
- INTS N/A
- EPS Growth
- SYT N/A
- INTS N/A
- EPS
- SYT 0.08
- INTS N/A
- Revenue
- SYT $149,124,408.00
- INTS N/A
- Revenue This Year
- SYT N/A
- INTS N/A
- Revenue Next Year
- SYT N/A
- INTS N/A
- P/E Ratio
- SYT $21.95
- INTS N/A
- Revenue Growth
- SYT 3.11
- INTS N/A
- 52 Week Low
- SYT $1.18
- INTS $1.50
- 52 Week High
- SYT $6.10
- INTS $5.94
- Technical
- Relative Strength Index (RSI)
- SYT 52.45
- INTS 49.26
- Support Level
- SYT $1.62
- INTS $1.84
- Resistance Level
- SYT $1.87
- INTS $2.27
- Average True Range (ATR)
- SYT 0.14
- INTS 0.28
- MACD
- SYT -0.01
- INTS -0.01
- Stochastic Oscillator
- SYT 56.67
- INTS 56.36
About SYT SYLA Technologies Co. Ltd.
SYLA Technologies Co Ltd is a property technology company. It provides asset management platform systems that facilitate real estate crowd-funding as well as the purchase and sale of real estate.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.